Main Menu

This technology includes a large panel of monoclonal antibodies (mAbs) against the spike glycoprotein, capable of recognizing intact SARS-CoV-2 virions with high affinity. Data to support SARS-CoV-2-specific binding include ELISA and label-free (biolayer interferometry) binding measurements using recombinant proteins, immunofluorescence in culture, immunofluorescence staining of tissue from infected patients, and virus neutralization assays.

This technology includes a Dengue-2 isolated virus for use as a cancer vaccine therapeutic.

This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.

Summary:

The National Cancer Institute (NCI) seeks licensees to further develop novel exonuclease VII (ExoVII) inhibitors as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial infection.   

This technology includes Klebsiella pneumoniae isolate to be used for research studies and diagnostic tests to detect antimicrobial resistance.

This technology includes an Escherichia coli isolate to be used in for research purposes and the development of diagnostics. The isolate is unique because it has the mcr-1 gene.

This technology includes an isolate of the yeast species Candida auris to be used in the development of diagnostic tools or anti-fungal for therapeutic use.

This technology includes natural Yellow Fever Virus, Zika Virus, and Powassan Virus isolates for various uses in research and development of diagnostics and immunizations.

Summary:

We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology.

The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system's response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there's a marked improvement in the immune system's ability to fight off the virus.